Corium International

Corium is a commercial-stage biopharmaceutical company leading the development of new transdermal healthcare products that provide clinicians with important treatment options for patients and their families. The Company is focused on developing, manufacturing and commercializing specialty CNS pharmaceuticals for our own pipeline. Corium's lead product, CorplexTM Donepezil, is a once-weekly transdermal patch containing the active ingredient in Aricept for the treatment of patients with mild, moderate and severe Alzheimer’s disease. The Company's transdermal technologies enable the development of innovative new products through the simple, safe and efficient delivery of both small and large molecule therapeutics, which provides significant clinical and commercial advantages, including valuable product lifecycle management.

Company Growth (employees)
Type
Public
HQ
Menlo Park, US
Founded
1999
Size (employees)
212 (est)
Corium International was founded in 1999 and is headquartered in Menlo Park, US

Key People at Corium International

Peter Staple

Peter Staple

President and Chief Executive Officer
Christina Dickerson

Christina Dickerson

Vice President of Corporate Development

Corium International Office Locations

Corium International has offices in Menlo Park and Kentwood
Menlo Park, US (HQ)
235 Constitution Dr
Kentwood, US
4558 50th St SE

Corium International Data and Metrics

Corium International Financial Metrics

Corium International's revenue was reported to be $7.3 m in Q2, 2017
USD

Revenue (Q2, 2017)

7.3 m

EBIT (Q2, 2017)

(9 m)

Market capitalization (22-Aug-2017)

241.3 m

Cash (30-Sep-2016)

39.8 m

EV

252.4 m
Corium International's current market capitalization is $241.3 m.
USDQ3, 2015Q1, 2015Q2, 2016Q3, 2016Q1, 2016Q2, 2017

Revenue

10.6 m7.5 m7 m10.6 m7 m7.3 m

R&D expense

3.5 m4.5 m5.6 m5.5 m6 m7.5 m

General and administrative expense

2.8 m3 m3 m3.1 m3 m3 m

Operating expense total

6.3 m7.5 m8.6 m8.6 m9 m10.5 m

EBIT

(4 m)(7.5 m)(8.6 m)(5.6 m)(8.4 m)(9 m)

EBIT margin, %

(38%)(99%)(123%)(52%)(121%)(123%)

Interest expense

1.9 m2 m2 m2 m2 m2 m

Interest income

5 k30 k58 k54 k28 k44 k

Pre tax profit

(5.9 m)(9.4 m)(10.5 m)(7.5 m)(10.4 m)(11 m)

Income tax expense

2 k3 k3 k3 k2 k2 k
USDFY, 2014FY, 2015FY, 2016

Cash

36.4 m72.2 m39.8 m

Accounts Receivable

4.2 m4.5 m4.3 m

Inventories

1.3 m1.4 m2.4 m

Current Assets

45.8 m81.8 m48.3 m

PP&E

12.7 m11.6 m11.1 m

Total Assets

65.7 m100.7 m67.2 m

Accounts Payable

2.5 m4 m2.7 m

Total Debt

51 m

Current Liabilities

8.5 m9.8 m8 m

Total Liabilities

64.3 m

Additional Paid-in Capital

114.1 m166.1 m170.3 m

Retained Earnings

(102.3 m)(130.8 m)(167.5 m)

Total Equity

11.8 m35.3 m2.9 m

Debt to Equity Ratio

17.9 x

Debt to Assets Ratio

0.8 x

Financial Leverage

5.6 x2.9 x23.5 x
USDFY, 2014FY, 2015FY, 2016

Accounts Receivable

(1 m)(293 k)125 k

Inventories

(255 k)(75 k)478 k

Accounts Payable

700 k1.4 m(1.2 m)

Cash From Operating Activities

(11.4 m)(20.7 m)(29.1 m)

Purchases of PP&E

(3.2 m)(973 k)(1.4 m)

Cash From Investing Activities

(3.7 m)(1.7 m)(3 m)

Long-term Borrowings

(484 k)(67 k)(72 k)

Cash From Financing Activities

37.9 m58.3 m(298 k)

Interest Paid

4.7 m5.6 m5.9 m

Income Taxes Paid

2 k2 k3 k
USDQ3, 2014Q1, 2014Q2, 2015Q3, 2015Q1, 2015Q2, 2016Q3, 2016Q1, 2016Q2, 2017

Depreciation and Amortization

141 k159 k162 k168 k177 k178 k

Accounts Receivable

4.5 m4.1 m4.9 m4.6 m3.1 m3.5 m4.1 m2.2 m3.4 m

Inventories

1.9 m2.7 m

Accounts Payable

2.6 m3.4 m2.6 m3.6 m2.7 m3.4 m3.1 m3.8 m3.7 m
USDY, 2017

EV/EBIT

-27.9 x

Revenue/Employee

34.6 k

Corium International Market Value History

Traffic Overview of Corium International

Corium International Online and Social Media Presence

Corium International Company Life and Culture

You may also be interested in